Baidu
map

BMC MED:磺脲类和二甲双胍联用或降2型糖尿病患者情感障碍风险

2012-12-10 高晓方 编译 BMC MED

  澳大利亚学者的一项研究表明,2型糖尿病患者的偶发情感障碍风险显著升高,磺脲类和二甲双胍联用则可使上述风险降至最低。论文于2012年11月29日在线发表于《英国医学委员会内科学》(BMC Medicine)。   既往研究显示包括抑郁在内的情感障碍、神经变性疾病痴呆和帕金森病在2型糖尿病患者中更为常见,二甲双胍治疗则有可能降低相关风险。神经变性疾病和抑郁或情感障碍可能存在共用的潜在诱

  澳大利亚学者的一项研究表明,2型糖尿病患者的偶发情感障碍风险显著升高,磺脲类和二甲双胍联用则可使上述风险降至最低。论文于2012年11月29日在线发表于《英国医学委员会内科学》(BMC Medicine)。

  既往研究显示包括抑郁在内的情感障碍、神经变性疾病痴呆和帕金森病在2型糖尿病患者中更为常见,二甲双胍治疗则有可能降低相关风险。神经变性疾病和抑郁或情感障碍可能存在共用的潜在诱发机制。此项研究共纳入762,753例受试者,并进行了为期12年的随访。通过将伴和未伴2型糖尿病的患者配对比较依据糖尿病状况的情感障碍风险。利用50岁以上受试者评估口服降糖药对情感障碍的影响。

  结果显示,在50岁以上的2型糖尿病患者中,未应用口服降糖药为情感障碍的危险因素之一[总体危险比(HR)2.62]。无论性别如何,联合应用磺脲类和二甲双胍均可显著降低2型糖尿病相关性情感障碍的发病率和相对风险。在单用二甲双胍、单用磺脲类和二者联用的患者中,情感障碍的HR分别为0.92、1.08和0.40,并且上述风险降低与用药顺序和胰岛素应用无关。

  相关领域的专家表示,上述结果并非全然出乎意料,目前亦有研究提示吡格列酮具有抗抑郁特性。目前神经精神疾病的新药研发已进入瓶颈期。磺脲类和二甲双胍可降低情感障碍风险的研究结果提示,基于临床观察和资料挖掘的偶然发现依然是有效的药物探寻方法。


Pathways to new drug discovery in neuropsychiatry

Abstract

There is currently a crisis in drug discovery for neuropsychiatric disorders, with a profound, yet unexpected drought in new drug development across the spectrum. In this commentary, the sources of this dilemma and potential avenues to redress the issue are explored. These include a critical review of diagnostic issues and of selection of participants for clinical trials, and the mechanisms for identifying new drugs and new drug targets. Historically, the vast majority of agents have been discovered serendipitously or have been modifications of existing agents. Serendipitous discoveries, based on astute clinical observation or data mining, remain a valid option, as is illustrated by the suggestion in the paper by Wahlqvist and colleagues that treatment with sulfonylurea and metformin reduces the risk of affective disorder. However, the identification of agents targeting disorder-related biomarkers is currently proving particularly fruitful. There is considerable hope for genetics as a purist, pathophysiologically valid pathway to drug discovery; however, it is unclear whether the science is ready to meet this promise. Fruitful paradigms will require a break from the orthodoxy, and creativity and risk may well be the fingerprints of success.

二甲双胍相关的拓展阅读:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1974552, encodeId=9a6a19e455203, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jul 16 23:02:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383126, encodeId=83e0138312694, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442135, encodeId=1cf51442135d0, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473677, encodeId=a3e414e3677be, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568706, encodeId=69f01568e0688, content=<a href='/topic/show?id=8b7d53129cc' target=_blank style='color:#2F92EE;'>#情感障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53129, encryptionId=8b7d53129cc, topicName=情感障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afcb15435989, createdName=天堂的云, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605864, encodeId=1300160586491, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1974552, encodeId=9a6a19e455203, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jul 16 23:02:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383126, encodeId=83e0138312694, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442135, encodeId=1cf51442135d0, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473677, encodeId=a3e414e3677be, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568706, encodeId=69f01568e0688, content=<a href='/topic/show?id=8b7d53129cc' target=_blank style='color:#2F92EE;'>#情感障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53129, encryptionId=8b7d53129cc, topicName=情感障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afcb15435989, createdName=天堂的云, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605864, encodeId=1300160586491, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1974552, encodeId=9a6a19e455203, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jul 16 23:02:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383126, encodeId=83e0138312694, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442135, encodeId=1cf51442135d0, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473677, encodeId=a3e414e3677be, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568706, encodeId=69f01568e0688, content=<a href='/topic/show?id=8b7d53129cc' target=_blank style='color:#2F92EE;'>#情感障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53129, encryptionId=8b7d53129cc, topicName=情感障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afcb15435989, createdName=天堂的云, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605864, encodeId=1300160586491, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1974552, encodeId=9a6a19e455203, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jul 16 23:02:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383126, encodeId=83e0138312694, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442135, encodeId=1cf51442135d0, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473677, encodeId=a3e414e3677be, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568706, encodeId=69f01568e0688, content=<a href='/topic/show?id=8b7d53129cc' target=_blank style='color:#2F92EE;'>#情感障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53129, encryptionId=8b7d53129cc, topicName=情感障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afcb15435989, createdName=天堂的云, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605864, encodeId=1300160586491, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1974552, encodeId=9a6a19e455203, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jul 16 23:02:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383126, encodeId=83e0138312694, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442135, encodeId=1cf51442135d0, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473677, encodeId=a3e414e3677be, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568706, encodeId=69f01568e0688, content=<a href='/topic/show?id=8b7d53129cc' target=_blank style='color:#2F92EE;'>#情感障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53129, encryptionId=8b7d53129cc, topicName=情感障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afcb15435989, createdName=天堂的云, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605864, encodeId=1300160586491, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1974552, encodeId=9a6a19e455203, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jul 16 23:02:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383126, encodeId=83e0138312694, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442135, encodeId=1cf51442135d0, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473677, encodeId=a3e414e3677be, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568706, encodeId=69f01568e0688, content=<a href='/topic/show?id=8b7d53129cc' target=_blank style='color:#2F92EE;'>#情感障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53129, encryptionId=8b7d53129cc, topicName=情感障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afcb15435989, createdName=天堂的云, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605864, encodeId=1300160586491, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Dec 12 06:02:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]

相关资讯

重视口服降糖药物的不良反应

      临床常用口服降糖药包括磺脲类以及非磺脲类(格列奈类)胰岛素促泌剂、双胍类、α糖苷酶抑制剂、噻唑烷二酮类(TZD)和二肽基肽酶Ⅳ(DPP-4)抑制剂等。所有降糖药物都可能发生副作用,并因药物类别和具体药品不同而异。总体而言,降糖药益处大于风险,但仍有一定比例应用降糖药的患者出现副作用,包括低血糖、体重增加、胃肠道不良反应、水肿等不良反应。据美国中毒控制中

T2DM患者口服降糖药失效后应尽快胰岛素治疗

  发表于2012年第6期《中国糖尿病杂志》上的一项研究表明, 2型糖尿病(T2DM)患者口服降糖药(OADs)失效后应尽快采用注射胰岛素、加强运动、控制饮食、减轻体重等干预治疗,可明显减少血管并发症发生。   研究选取了住院及门诊患者453例,分为治疗组(232例)和对照组(221例)。治疗组注射胰岛素,严格控制FPG在6mmol/L左右;控制饮食,每日摄入热卡25kcal/kg;每

EASD2012:中国口服降糖药应用状况堪忧

  2012年EASD大会上,中国学者进行了3场口头报告和19项壁报展示。其中,北京大学人民医院的一项报告表明,胰岛素促泌剂为中国2型糖尿病患者最常用的口服降糖药,并可能是低血糖高发和血糖控制不佳的原因。应用磺脲类或格列奈类单药治疗的患者更有可能改变治疗方案,疗效不佳为其主要原因。   研究背景   中国拥有世界最大的糖尿病人群,20岁以上糖尿病患者接近1亿。基于循证医学指南的糖尿病管理和治疗

Baidu
map
Baidu
map
Baidu
map